A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk

American Journal of Cardiology

Volumn 117, Issue 1, 2016, Pages 40-47

  Kiyosue, Arihiro ^a,b   Honarpour, Narimon ^c   Kurtz, Christopher ^c   Xue, Allen ^c   Wasserman, Scott M ^c   Hirayama, Atsushi ^d  

^a UNIVERSITY OF TOKYO   (Japan)

^b Tokyo Eki Center Building Clinic   (Japan)

^c AMGEN INC   (United States)

^d NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; EVOLOCUMAB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BRONCHITIS; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GASTROENTERITIS; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INJECTION SITE REACTION; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUSCLE DISEASE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHARYNGITIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; UNSPECIFIED SIDE EFFECT; AGED; BLOOD; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; HYPERLIPIDEMIAS; JAPAN; MORBIDITY; PHASE 3 CLINICAL TRIAL; PROCEDURES; RISK ASSESSMENT; RISK FACTOR; SUBCUTANEOUS DRUG ADMINISTRATION; TRENDS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CARDIOVASCULAR DISEASES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; INJECTIONS, SUBCUTANEOUS; JAPAN; LIPIDS; MALE; MIDDLE AGED; MORBIDITY; RISK ASSESSMENT; RISK FACTORS; YOUNG ADULT;

EID: 84959431587     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2015.10.021     Document Type: Article

References (30)

1. J.D. Horton, J.C. Cohen, and H.H. Hobbs Molecular biology of PCSK9: its role in LDL metabolism Trends Biochem Sci 32 2007 71 77
2. J.C. Chan, D.E. Piper, Q. Cao, D. Liu, C. King, W. Wang, J. Tang, Q. Liu, J. Higbee, Z. Xia, Y. Di, S. Shetterly, Z. Arimura, H. Salomonis, W.G. Romanow, S.T. Thibault, R. Zhang, P. Cao, X.P. Yang, T. Yu, M. Lu, M.W. Retter, G. Kwon, K. Henne, O. Pan, M.M. Tsai, B. Fuchslocher, E. Yang, L. Zhou, K.J. Lee, M. Daris, J. Sheng, Y. Wang, W.D. Shen, W.C. Yeh, M. Emery, N.P. Walker, B. Shan, M. Schwarz, and S.M. Jackson A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates Proc Natl Acad Sci U S A 106 2009 9820 9825
3. Y.G. Ni, J.H. Condra, L. Orsatti, X. Shen, S. Di Marco, S. Pandit, M.J. Bottomley, L. Ruggeri, R.T. Cummings, R.M. Cubbon, J.C. Santoro, A. Ehrhardt, D. Lewis, T.S. Fisher, S. Ha, L. Njimoluh, D.D. Wood, H.A. Hammond, D. Wisniewski, C. Volpari, A. Noto, P. Lo Surdo, B. Hubbard, A. Carfi, and A. Sitlani A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake J Biol Chem 285 2010 12882 12891
4. L. Zhang, T. McCabe, J.H. Condra, Y.G. Ni, L.B. Peterson, W. Wang, A.M. Strack, F. Wang, S. Pandit, H. Hammond, D. Wood, D. Lewis, R. Rosa, V. Mendoza, A.M. Cumiskey, D.G. Johns, B.C. Hansen, X. Shen, N. Geoghagen, K. Jensen, L. Zhu, K. Wietecha, D. Wisniewski, L. Huang, J.Z. Zhao, R. Ernst, R. Hampton, P. Haytko, F. Ansbro, S. Chilewski, J. Chin, L.J. Mitnaul, A. Pellacani, C.P. Sparrow, Z. An, W. Strohl, B. Hubbard, A.S. Plump, D. Blom, and A. Sitlani An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes Int J Biol Sci 8 2012 310 327
5. D.J. Blom, T. Hala, M. Bolognese, M.J. Lillestol, P.D. Toth, L. Burgess, R. Ceska, E. Roth, M.J. Koren, C.M. Ballantyne, M.L. Monsalvo, K. Tsirtsonis, J.B. Kim, R. Scott, S.M. Wasserman, E.A. Stein DESCARTES Investigators A 52-week placebo-controlled trial of evolocumab in hyperlipidemia N Engl J Med 370 2014 1809 1819
6. R.P. Giugliano, N.R. Desai, P. Kohli, W.J. Rogers, R. Somaratne, F. Huang, T. Liu, S. Mohanavelu, E.B. Hoffman, S.T. McDonald, T.E. Abrahamsen, S.M. Wasserman, R. Scott, M.S. Sabatine LAPLACE-TIMI 57 Investigators Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study Lancet 380 2012 2007 2017
7. A. Hirayama, N. Honarpour, M. Yoshida, S. Yamashita, F. Huang, S.M. Wasserman, and T. Teramoto Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk-primary results from the phase 2 YUKAWA study Circ J 78 2014 1073 1082
8. M.J. Koren, P. Lundqvist, M. Bolognese, J.M. Neutel, M.L. Monsalvo, J. Yang, J.B. Kim, R. Scott, S.M. Wasserman, H. Bays MENDEL-2 Investigators Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab J Am Coll Cardiol 63 2014 2531 2540
9. M.J. Koren, R. Scott, J.B. Kim, B. Knusel, T. Liu, L. Lei, M. Bolognese, and S.M. Wasserman Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study Lancet 380 2012 1995 2006
10. F. Raal, R. Scott, R. Somaratne, I. Bridges, G. Li, S.M. Wasserman, and E.A. Stein Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial Circulation 126 2012 2408 2417
11. F.J. Raal, N. Honarpour, D.J. Blom, G.K. Hovingh, F. Xu, R. Scott, S.M. Wasserman, E.A. Stein TESLA Investigators Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial Lancet 385 2015 341 350
12. F.J. Raal, E.A. Stein, R. Dufour, T. Turner, F. Civeira, L. Burgess, G. Langslet, R. Scott, A.G. Olsson, D. Sullivan, G.K. Hovingh, B. Cariou, I. Gouni-Berthold, R. Somaratne, I. Bridges, R. Scott, S.M. Wasserman, D. Gaudet RUTHERFORD-2 Investigators PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial Lancet 385 2015 331 340
13. J.G. Robinson, B.S. Nedergaard, W.J. Rogers, J. Fialkow, J.M. Neutel, D. Ramstad, R. Somaratne, J.C. Legg, P. Nelson, R. Scott, S.M. Wasserman, R. Weiss LAPLACE-2 Investigators Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial JAMA 311 2014 1870 1882
14. E.A. Stein, N. Honarpour, S.M. Wasserman, F. Xu, R. Scott, and F.J. Raal Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia Circulation 128 2013 2113 2120
15. E. Stroes, D. Colquhoun, D. Sullivan, F. Civeira, R.S. Rosenson, G.F. Watts, E. Bruckert, L. Cho, R. Dent, B. Knusel, A. Xue, R. Scott, S.M. Wasserman, M. Rocco GAUSS-2 Investigators Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab J Am Coll Cardiol 63 2014 2541 2548
16. D. Sullivan, A.G. Olsson, R. Scott, J.B. Kim, A. Xue, V. Gebski, S.M. Wasserman, and E.A. Stein Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial JAMA 308 2012 2497 2506
17. T. Teramoto, J. Sasaki, S. Ishibashi, S. Birou, H. Daida, S. Dohi, G. Egusa, T. Hiro, K. Hirobe, M. Iida, S. Kihara, M. Kinoshita, C. Maruyama, T. Ohta, T. Okamura, S. Yamashita, M. Yokode, and K. Yokote Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan - 2012 version J Atheroscler Thromb 20 2013 517 523
18. B.G. Nordestgaard, M.J. Chapman, and H.N. Ginsberg Lipoprotein(a): EAS recommendations for screening, desirable levels and management: A Handbook for Clinicians 2012 Sherborne Gibbs Ltd Warwickshire, UK
19. R. Romagnuolo, C. Scipione, M.B. Boffa, S.M. Marcovina, N.G. Seidah, and M.L. Koschinsky Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor J Biol Chem 290 2015 11649 11662
20. F.J. Raal, R.P. Giugliano, M.S. Sabatine, M.J. Koren, G. Langslet, H. Bays, D. Blom, M. Eriksson, R. Dent, S.M. Wasserman, F. Huang, A. Xue, M. Albizem, R. Scott, and E.A. Stein Reduction in lipoprotein (a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials J Am Coll Cardiol 63 2014 1278 1288
21. A.R. Sharrett, C.M. Ballantyne, S.A. Coady, G. Heiss, P.D. Sorlie, D. Catellier, and W. Patsch Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the atherosclerosis risk in communities (ARIC) study Circulation 104 2001 1108 1113
22. R. Xu, M. Peach, M. Tracy, L. Hamilton, S. Djedjos, R. Dent, D. Fitzpatrick, R. Scott, and S.M. Wasserman Effects of evolocumab (AMG 145) as a monotherapy or in combination with statins on lipoprotein particles and subclasses Circulation 130 2014 A16955
23. C.G. Santos-Gallego, J.J. Badimon, and R.S. Rosenson Beginning to understand high-density lipoproteins Endocrinol Metab Clin North Am 43 2014 913 947
24. M.S. Sabatine, R.P. Giugliano, S.D. Wiviott, F.J. Raal, D.J. Blom, J. Robinson, C.M. Ballantyne, R. Somaratne, J. Legg, S.M. Wasserman, R. Scott, M.J. Koren, E.A. Stein Open-Label Study of Long-Term Evaluation against LDL Cholesterol Investigators Efficacy and safety of evolocumab in reducing lipids and cardiovascular events N Engl J Med 372 2015 1500 1509
25. Cholesterol Treatment Trialists (CTT) Collaboration C. Baigent, L. Blackwell, J. Emberson, L. Holland, C. Reith, N. Bhala, R. Peto, E. Barnes, A. Keech, J. Simes, and R. Collins Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
26. H. Buchwald, R.L. Varco, J.P. Matts, J.M. Long, L.L. Fitch, G.S. Campbell, M.B. Pearce, A.E. Yellin, W.A. Edmiston, R.D. Smink Jr., H.S. Sawin, C.T. Campos, B.J. Hansen, N. Tuna, J.N. Karnegis, M.E. Sanmarco, K. Amplatz, W.R. Castaneda-Zuniga, D.W. Hunter, J.K. Bissett, F.J. Weber, J.W. Stevenson, A.S. Leon, T.C. Chalmers POSCH Group Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH) N Engl J Med 323 1990 946 955
27. C.P. Cannon, M.A. Blazing, R.P. Giugliano, A. McCagg, J.A. White, P. Theroux, H. Darius, B.S. Lewis, T.O. Ophuis, J.W. Jukema, G.M. De Ferrari, W. Ruzyllo, P. De Lucca, K. Im, E.A. Bohula, C. Reist, S.D. Wiviott, A.M. Tershakovec, T.A. Musliner, E. Braunwald, R.M. Califf IMPROVE-IT Investigators Ezetimibe added to statin therapy after acute coronary syndromes N Engl J Med 372 2015 2387 2397
28. US Department of Health and Human Services Lipid Research Clinics Manual of Laboratory Operations. Lipid and Lipoprotein Analysis (Revised). Department of Health and Human Services Publication (NIH) #75-67815 1982 Government Printing Office Washington, DC
29. N.J. Stone, J. Robinson, A.H. Lichtenstein, C.N. Merz, C.B. Blum, R.H. Eckel, A.C. Goldberg, D. Gordon, D. Levy, D.M. Lloyd-Jones, P. McBride, J.S. Schwartz, S.T. Shero, S.C. Smith Jr., K. Watson, P.W. Wilson, K.M. Eddleman, N.M. Jarrett, K. LaBresh, L. Nevo, J. Wnek, J.L. Anderson, J.L. Halperin, N.M. Albert, B. Bozkurt, R.G. Brindis, L.H. Curtis, D. DeMets, J.S. Hochman, R.J. Kovacs, E.M. Ohman, S.J. Pressler, F.W. Sellke, W.K. Shen, S.C.J. Smith, G.F. Tomaselli American College of Cardiology/American Heart AssociationTask Force on Practice Guidelines 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines Circulation 125 2014 S1 S45
30. J.G. Robinson, M. Farnier, M. Krempf, J. Bergeron, G. Luc, M. Averna, E.S. Stroes, G. Langslet, F.J. Raal, M.E. Shahawy, M.J. Koren, N.E. Lepor, C. Lorenzato, R. Pordy, U. Chaudhari, J.J. Kastelein ODYSSEY LONG TERM Investigators Efficacy and safety of alirocumab in reducing lipids and cardiovascular events N Engl J Med 372 2015 1489 1499